FHFrans M. Helmerhorst

Frans M. Helmerhorst

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frans M. Helmerhorst has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fertiliteitsstoornissen

    by Frans M. Helmerhorst

  • Open Access

    Development of the follicular basement membrane during human gametogenesis and early folliculogenesis

    by A Marijne Heeren, Liesbeth van Iperen, Daniëlle B Klootwijk, Ana de Melo Bernardo, Matthias S Roost, Maria M Gomes Fernandes, Leonie A Louwe, Carina G Hilders, Frans M Helmerhorst, Lucette A J van der Westerlaken, et al.

    In society, there is a clear need to improve the success rate of techniques to restore fertility. Therefore a deeper knowledge of the dynamics of the complex molecular environment that regulates human gametogenesis and (early) folliculogenesis in vivo is necessary. Here, we have studied these processes focusing on the formation of the follicular basement membrane (BM) in vivo. The distribution of the main components of the extracellular matrix (ECM) collagen IV, laminin and fibronectin by week 10 of gestation (W10) in the ovarian cortex revealed the existence of ovarian cords and of a distinct mesenchymal compartment, resembling the organization in the male gonads. By W17, the first primordial follicles were assembled individually in that (cortical) mesenchymal compartment and were already encapsulated by a BM of collagen IV and laminin, but not fibronectin. In adults, in the primary and secondary follicles, collagen IV, laminin and to a lesser extent fibronectin were prominent in the follicular BM. The ECM-molecular niche compartimentalizes the female gonads from the time of germ cell colonization until adulthood. This knowledge may contribute to improve methods to recreate the environment needed for successful folliculogenesis in vitro and that would benefit a large number of infertility patients.


  • Open Access

    The significance of fragile X mental retardation gene 1 CGG repeat sizes in the normal and intermediate range in women with primary ovarian insufficiency

    by M. Voorhuis, N. C. Onland-Moret, F. Janse, H. K. Ploos van Amstel, A. J. Goverde, C. B. Lambalk, J. S. E. Laven, Y. T. van der Schouw, F. J. M. Broekmans, B. C. J. M. Fauser, et al.

    Are fragile X mental retardation gene 1 (FMR1) CGG repeats in the normal and intermediate range (up to 55 repeats) associated with primary ovarian insufficiency (POI) in a large case–control study? No association was found between CGG repeats of intermediate size and POI compared with controls. CGG repeats in the FMR1 gene in the premutation range (55–200 repeats) have consistenly associated with POI. Intermediate range CGG repeats have been considered for a potential association with POI. A case–control study in 375 well-phenotyped Dutch women diagnosed with POI and 3368 controls with natural menopause ≥40 years of age. The FMR1 CGG repeat number was determined by PCR amplification in women diagnosed with POI and women with a known age at natural menopause ≥40 years. The prevalence of intermediate sized CGG repeats (45–54 repeats) was compared between POI cases and controls using Fisher's exact test. Differences in mean CGG repeat lengths on allele 1 and allele 2 between POI cases and controls were tested using analysis of variance. The frequency of intermediate sized CGG repeats on the allele with the longest triple repeat number was not statistically significantly different between POI cases and controls (2.7 and 3.8%, respectively, odds ratio 0.72, 95% confidence interval: 0.38–1.39, P = 0.38). In women with POI, linear regression analysis for age at POI diagnosis and CGG repeat size also failed to show any association (β = −0.018, P = 0.74). FMR1 CGG repeat lengths in POI cases and controls were genotyped in two different laboratories. The distributions of CGG repeats may vary among the different ethnic populations in our study. Also, in our study women with primary amenorrhea (N = 17) were included in the POI group. We found no association between intermediate sized CGG repeats and POI compared with controls. Therefore, a role for FMR1 CGG repeat sizes up to 55 repeats in the ovarian ageing process may be questioned. Moreover, there seems limited value in the evaluation of normal- and intermediate FMR1 repeat size in the diagnostic work-up of women affected by POI, or for prognostic purposes in women at risk of developing POI. The Prospect-EPIC study was funded by ‘Europe Against Cancer’ Program of the European Commission (SANCO); the Dutch Ministry of Health; the Dutch Cancer Society; ZonMW the Netherlands Organization for Health Research and Development; World Cancer Research Fund (WCRF) and the Dutch Heart Association.


  • Open Access

    Hormonal Contraceptive Use After Venous Thrombosis: Practice From 1999 to 2004

    by Stegeman, Bernardine H. Stegeman, Hetty Jolink, Frans M. Helmerhorst, Frits R. Rosendaal, Astrid van Hylckama Vlieg

    Background: Current guidelines state that women using combined hormonal contraceptives should stop using these preparations after a venous thrombosis. The aim of this study was to assess to what extent these guidelines are followed in daily practice. Methods: Women younger than 50 years with a hormonal contraceptive-associated venous thrombosis were selected from the Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA) study. Data on hormonal contraceptive use after the event and advice from a physician were collected at venepuncture and through a follow-up study, respectively. Risk differences (RDs) with 95% confidence interval (95% CI) were calculated. Results: Seven hundred three women were included with a mean follow-up at venepuncture of 10.8 months (range: 2.1 to 35.4 months). Five hundred twenty-one (74%) women stopped hormonal contraceptive use, 63 (9%) changed to a different preparation and 119 (17%) continued to use their preparation. One hundred forty-three (21%) of 682 women using a combined oral contraceptive at the thrombotic event were still using a combined preparation after the event. Women who continued their contraceptive use had less often a positive family history of venous thrombosis and more often surgery (RD 19% (95% CI: 9 to 30%)) or a plaster cast (RD 17% (95% CI: 3 to 34%)) at the thrombotic event than women who stopped. Out of 332 women using a combined preparation and who received advice from a physician to stop, 39 (12%) continued to use their current contraceptive. Conclusions: The finding that women continue their combined oral contraceptive use after receiving advice to stop is a real concern, in particular because this use could increase the risk of a recurrence. J Endocrinol Metab. 2014;4(3):56-63 doi: http://dx.doi.org/10.14740/jem221w

  • Open Access

    The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial

    by Theodora C van Tilborg, Marinus Jc Eijkemans, Joop Se Laven, Carolien Am Koks, Jan Peter de Bruin, Gabrielle J Scheffer, Ron Jt van Golde, Kathrin Fleischer, Annemieke Hoek, Annemiek W Nap, et al.

    Costs of in vitro fertilisation (IVF) are high, which is partly due to the use of follicle stimulating hormone (FSH). FSH is usually administered in a standard dose. However, due to differences in ovarian reserve between women, ovarian response also differs with potential negative consequences on pregnancy rates. A Markov decision-analytic model showed that FSH dose individualisation according to ovarian reserve is likely to be cost-effective in women who are eligible for IVF. However, this has never been confirmed in a large randomised controlled trial (RCT). The aim of the present study is to assess whether an individualised FSH dose regime based on an ovarian reserve test (ORT) is more cost-effective than a standard dose regime.


  • Quadriphasic versus monophasic oral contraceptives for contraception

    by Huib Aam Van Vliet, Marjolein Raps, Laureen M Lopez, Frans M Helmerhorst


  • Top Cited Papers

    PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis

    by P. C. M. de Groot, O. M. Dekkers, J. A. Romijn, S. W. M. Dieben, F. M. Helmerhorst

    BACKGROUND Patients with polycystic ovary syndrome (PCOS) are at risk of arterial disease. We examined the risk of (non)fatal coronary heart disease (CHD) or stroke in patients with PCOS and ovulatory women without PCOS, and assessed whether obesity might explain a higher risk of CHD or stroke. METHODS We performed a systematic review and meta-analysis of controlled observational studies. Four definitions of PCOS were considered: World Health Organization type II anovulation, National Institutes of Health criteria, Rotterdam consensus and Androgen-excess criteria. Obesity was defined as BMI > 30 kg/m2 and/or waist circumference >88 cm. Study quality was assessed using the Newcastle–Ottawa Scale. Primary outcome was fatal/non-fatal CHD or stroke. Definitions of CHD and stroke were based on criteria used by the various authors. The effect measure was the pooled relative risk in a random effects model. Risk ratios and rate ratios were combined here. RESULTS After identifying 1340 articles, 5 follow-up studies published between 2000 and 2008 were included. The studies showed heterogeneity in design, definitions and quality. In a random effects model the relative risk for CHD or stroke were 2.02 comparing women with PCOS to women without PCOS (95% confidence interval 1.47, 2.76). Pooling the two studies with risk estimates adjusted for BMI showed a relative risk of 1.55 (1.27, 1.89). CONCLUSIONS This meta-analysis showed a 2-fold risk of arterial disease for patients with PCOS relative to women without PCOS. BMI adjustment did not affect this finding, suggesting the increased risk for cardiovascular events in PCOS is not completely related to a higher BMI in patients with PCOS.


  • Open Access

    Vaginal misoprostol prior to insertion of an intrauterine device: an RCT

    by Kirsten Dijkhuizen, Olaf M. Dekkers, C. A. G. Holleboom, Christianne J.M. de Groot, Bart W.J. Hellebrekers, Godelieve J.J. van Roosmalen, Catharina A.H. Janssen, Frans M. Helmerhorst

    Misoprostol is an agent that may ripen the cervix in nonpregnant women. Here, we investigate whether vaginal misoprostol administered prior to intrauterine device (IUD) insertion reduces the number of failed insertions, insertion-related complications and pain during insertion. We conducted a double-blinded, multicenter randomized controlled trial among patients requesting an IUD. Nulli- and multi-parous women were included, and both copper-containing and levonorgestrel-releasing IUDs were used. Participants were allocated to either 400 μg misoprostol or placebo (administered 3h prior to IUD insertion). The primary outcome measure was failed insertion. Secondary outcome measures were insertion-related complications, pain, difficulty of insertion and side-effects. Two hundred and seventy participants were randomized. After drop out for various reasons (mainly no show), 199 participants had an IUD inserted; 102 received misoprostol and 97 received placebo. Only three insertions failed; two in the misoprostol group and one in the placebo group [P = 0.59, relative risk (RR) 1.9, 95% confidence interval (CI) 0.2–20.6]. The overall incidence of insertion-related complications was 21.8% in the misoprostol versus 19.1% in the placebo group (mainly vasovagal-like reactions) and did not differ between groups (P = 0.65, RR 1.1, 95% CI 0.7–2.0). No difference in pain scores between groups was found. Side-effects were more common in the misoprostol group (P = 0.05, RR 1.3, 95% CI 1.0–1.7). The study showed no benefit for use of misoprostol prior to IUD insertion. However, there is a tendency of possible harm regarding side-effects. Therefore, we would not recommend standard pretreatment with misoprostol. The trial was registered in the European Clinical Trials Database EudraCT 2006-006897-60.